Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Sophia Genetics to Comarket NGS Solutions for Clinical Dx

NEW YORK (GenomeWeb) – Sophia Genetics said today that it has signed a co-marketing agreement with Illumina that allows the companies jointly market their respective products and solutions to hospitals and clinical laboratories.

Initially, the companies will market their combined products to customers in the EMEA region, Sophia said. Financial and other terms of the deal were not disclosed.

"We are very pleased to enter into this agreement with Illumina to speed the adoption of NGS in clinical diagnostics," Sophia Genetics CEO and Co-founder Jurgi Camblong said in a statement. "Today's agreement with Illumina underlines the value of state-of-the-art analytical solutions in routine diagnostics which truly unlock the promises of data-driven medicine for patients around the world."

Last month, Sophia Genetics announced a deal that pairs Sophia's Data Driven Medicine platform with Devyser's diagnostic kits for hereditary breast cancer and cystic fibrosis testing. Devyser's BRCA kit covers all coding regions, promoter, and exon-intron boundaries of BRCA1 and BRCA2 and can be used to detect both germline and somatic mutations in both genes. The cystic fibrosis kit covers CTFR mutations in coding regions, intron/exon boundaries and promoter regions, as well as deep intronic sequences and large structural deletions.